Zhang Huiyuan, Hu Hongbo, Greeley Nathaniel, Jin Jin, Matthews Allison J, Ohashi Erika, Caetano Mauricio S, Li Haiyan S, Wu Xuefeng, Mandal Pijus K, McMurray John S, Moghaddam Seyed Javad, Sun Shao-Cong, Watowich Stephanie S
Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
1] Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA [2] The University of Texas Graduate School of Biomedical Sciences, Houston, Texas 77030, USA.
Nat Commun. 2014 Dec 15;5:5798. doi: 10.1038/ncomms6798.
The transcriptional regulator STAT3 curbs pro-inflammatory cytokine production mediated by NF-κB signalling in innate immune cells, yet the mechanism by which this occurs has been unclear. Here we identify STAT3 as a pivotal negative regulator of Ubc13, an E2 ubiquitin-conjugating enzyme that facilitates TRAF6 K63-linked ubiquitination and NF-κB activation. Ubc13 accumulates intracellularly in the absence of STAT3. Depletion of Ubc13 in Stat3-deficient macrophages subdues excessive RANKL- or LPS-dependent gene expression, indicating that Ubc13 overexpression mediates enhanced transcriptional responses in the absence of STAT3. In RANKL-activated macrophages, STAT3 is stimulated by autocrine IL-6 and inhibits accrual of Ets-1, Set1 methyltransferase and trimethylation of histone H3 lysine 4 (H3K4me3) at the Ube2n (Ubc13) promoter. These results delineate a mechanism by which STAT3 operates as a transcriptional repressor on Ube2n, thus modulating NF-κB activity by regulation of Ubc13 abundance. Our data suggest that this pathway plays important roles in bone homeostasis and restraint of inflammation.
J Nutr Biochem. 2012-8-24
Proc Natl Acad Sci U S A. 2007-4-10
Invest Ophthalmol Vis Sci. 2025-1-2
Nat Immunol. 2011-7-19
Proc Natl Acad Sci U S A. 2011-7-18